FSFredrik Svensson

Fredrik Svensson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fredrik Svensson has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design and synthesis of a chemically diverse, lead-like DNA-encoded library from sequential amide coupling

    by Cameron E. Taylor, Grace Roper, Rhianna Young, Fredrik Svensson, Andreas Brunschweiger, Sam Butterworth, Andrew G. Leach, Michael J. Waring

    Accessible synthesis of DNA-encoded libraries of up to 3 million-members via sequential amide coupling, validated by CAIX screening. In silico analysis showed lead-like properties, and the libraries are available to support academic drug discovery.


  • Computational Hit Finding: An Industry Perspective

    by Paraskevi Gkeka, Fredrik Svensson, Carlos Roca Magadán, Marcel John de Groot, Steven V. Jerome

    Computational hit finding, particularly virtual screening, has been a mainstay of drug discovery campaigns for decades, providing a cost-efficient complement to wet experiments. Innovation in this space slowed considerably as these approaches converged around mature software programs and stock chemical libraries up to ∼10 million in size. Recently, however, powered by massive increases in computational power, the emergence of ultralarge make-on-demand virtual libraries, the development of large capacity neural networks, the expansion of the domain of applicability of free energy calculations, and advances in protein structure prediction, the virtual screening field is currently seeing major change. We present a guide from industry practitioners summarizing key aspects on the changing computational hit finding landscape including practical recommendations for building a performant end-to-end screening workflow, strategies to mitigate risk by avoiding common pitfalls, determining success criteria, and a brief discussion of emerging technologies likely to impact drug discovery in the near future.


  • Open Access

    Designed switch from covalent to non-covalent inhibitors of carboxylesterase Notum activity

    by Benjamin N. Atkinson, Nicky J. Willis, Yuguang Zhao, Chandni Patel, Sarah Frew, Kathryn Costelloe, Lorenza Magno, Fredrik Svensson, E. Yvonne Jones, Paul V. Fish


  • Open Access

    Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit

    by Nicky J. Willis, William Mahy, James Sipthorp, Yuguang Zhao, Hannah L. Woodward, Benjamin N. Atkinson, Elliott D. Bayle, Fredrik Svensson, Sarah Frew, Fiona Jeganathan, et al.

    Notum is a carboxylesterase that suppresses Wnt signaling through deacylation of an essential palmitoleate group on Wnt proteins. There is a growing understanding of the role Notum plays in human diseases such as colorectal cancer and Alzheimer's disease, supporting the need to discover improved inhibitors, especially for use in models of neurodegeneration. Here, we have described the discovery and profile of 8l (ARUK3001185) as a potent, selective, and brain-penetrant inhibitor of Notum activity suitable for oral dosing in rodent models of disease. Crystallographic fragment screening of the Diamond-SGC Poised Library for binding to Notum, supported by a biochemical enzyme assay to rank inhibition activity, identified 6a and 6b as a pair of outstanding hits. Fragment development of 6 delivered 8l that restored Wnt signaling in the presence of Notum in a cell-based reporter assay. Assessment in pharmacology screens showed 8l to be selective against serine hydrolases, kinases, and drug targets.


  • Open Access

    Consideration of predicted small-molecule metabolites in computational toxicology

    by Marina Garcia de Lomana, Fredrik Svensson, Andrea Volkamer, Miriam Mathea, Johannes Kirchmair

    Xenobiotic metabolism has evolved as a key protective system of organisms against potentially harmful chemicals or compounds typically not present in a particular organism. The system's primary purpose is to chemically transform xenobiotics into metabolites that can be excreted via renal or biliary routes. However, in a minority of cases, the metabolites formed are toxic, sometimes even more toxic than the parent compound. Therefore, the consideration of xenobiotic metabolism clearly is of importance to the understanding of the toxicity of a compound. Nevertheless, most of the existing computational approaches for toxicity prediction do not explicitly take metabolism into account and it is currently not known to what extent the consideration of (predicted) metabolites could lead to an improvement of toxicity prediction. In order to study how predictive metabolism could help to enhance toxicity prediction, we explored a number of different strategies to integrate predictions from a state-of-the-art metabolite structure predictor and from modern machine learning approaches for toxicity prediction. We tested the integrated models on five toxicological endpoints and assays, including in vitro and in vivo genotoxicity assays (AMES and MNT), two organ toxicity endpoints (DILI and DICC) and a skin sensitization assay (LLNA). Overall, the improvements in model performance achieved by including metabolism data were minor (up to +0.04 in the F1 scores and up to +0.06 in MCCs). In general, the best performance was obtained by averaging the probability of toxicity predicted for the parent compound and the maximum probability of toxicity predicted for any metabolite. Moreover, including metabolite structures as further input molecules for model training slightly improved the toxicity predictions obtained by this averaging approach. However, the high complexity of the metabolic system and associated uncertainty about the likely metabolites apparently limits the benefit of considering predicted metabolites in toxicity prediction.


  • Virtual Screening Directly Identifies New Fragment-Sized Inhibitors of Carboxylesterase Notum with Nanomolar Activity

    by David Steadman, Benjamin N. Atkinson, Yuguang Zhao, Nicky J. Willis, Sarah Frew, Amy Monaghan, Chandni Patel, Emma Armstrong, Kathryn Costelloe, Lorenza Magno, et al.

    Notum is a negative regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity. Inhibitors of Notum could be of use in diseases where dysfunctional Notum activity is an underlying cause. A docking-based virtual screen (VS) of a large commercial library was used to shortlist 952 compounds for experimental validation as inhibitors of Notum. The VS was successful with 31 compounds having an IC50 < 500 nM. A critical selection process was then applied with two clusters and two singletons (1–4d) selected for hit validation. Optimization of 4d guided by structural biology identified potent inhibitors of Notum activity that restored Wnt/β-catenin signaling in cell-based models. The [1,2,4]triazolo[4,3-b]pyradizin-3(2H)-one series 4 represent a new chemical class of Notum inhibitors and the first to be discovered by a VS campaign. These results demonstrate the value of VS with well-designed docking models based on X-ray structures.


  • Open Access

    Synergy conformal prediction applied to large-scale bioactivity datasets and in federated learning

    by Ulf Norinder, Ola Spjuth, Fredrik Svensson

    Confidence predictors can deliver predictions with the associated confidence required for decision making and can play an important role in drug discovery and toxicity predictions. In this work we investigate a recently introduced version of conformal prediction, synergy conformal prediction, focusing on the predictive performance when applied to bioactivity data. We compare the performance to other variants of conformal predictors for multiple partitioned datasets and demonstrate the utility of synergy conformal predictors for federated learning where data cannot be pooled in one location. Our results show that synergy conformal predictors based on training data randomly sampled with replacement can compete with other conformal setups, while using completely separate training sets often results in worse performance. However, in a federated setup where no method has access to all the data, synergy conformal prediction is shown to give promising results. Based on our study, we conclude that synergy conformal predictors are a valuable addition to the conformal prediction toolbox.


  • Open Access

    Structural Insights into Notum Covalent Inhibition

    by Yuguang Zhao, Fredrik Svensson, David Steadman, Sarah Frew, Amy Monaghan, Magda Bictash, Tiago Moreira, Rod Chalk, Weixian Lu, Paul V. Fish, et al.

    The carboxylesterase Notum hydrolyzes a palmitoleate moiety from Wingless/Integrated(Wnt) ligands and deactivates Wnt signaling. Notum inhibitors can restore Wnt signaling which may be of therapeutic benefit for pathologies such as osteoporosis and Alzheimer’s disease. We report the identification of a novel class of covalent Notum inhibitors, 4-(indolin-1-yl)-4-oxobutanoate esters. High-resolution crystal structures of the Notum inhibitor complexes reveal a common covalent adduct formed between the nucleophile serine-232 and hydrolyzed butyric esters. The covalent interaction in solution was confirmed by mass spectrometry analysis. Inhibitory potencies vary depending on the warheads used. Mechanistically, the resulting acyl-enzyme intermediate carbonyl atom is positioned at an unfavorable angle for the approach of the active site water, which, combined with strong hydrophobic interactions with the enzyme pocket residues, hinders the intermediate from being further processed and results in covalent inhibition. These insights into Notum catalytic inhibition may guide development of more potent Notum inhibitors.


  • Deep Learning-Based Conformal Prediction of Toxicity

    by Jin Zhang, Ulf Norinder, Fredrik Svensson

    Predictive modeling for toxicity can help reduce risks in a range of applications and potentially serve as the basis for regulatory decisions. However, the utility of these predictions can be limited if the associated uncertainty is not adequately quantified. With recent studies showing great promise for deep learning-based models also for toxicity predictions, we investigate the combination of deep learning-based predictors with the conformal prediction framework to generate highly predictive models with well-defined uncertainties. We use a range of deep feedforward neural networks and graph neural networks in a conformal prediction setting and evaluate their performance on data from the Tox21 challenge. We also compare the results from the conformal predictors to those of the underlying machine learning models. The results indicate that highly predictive models can be obtained that result in very efficient conformal predictors even at high confidence levels. Taken together, our results highlight the utility of conformal predictors as a convenient way to deliver toxicity predictions with confidence, adding both statistical guarantees on the model performance as well as better predictions of the minority class compared to the underlying models.


  • Open Access

    TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation

    by Lorenza Magno, Tom D. Bunney, Emma Mead, Fredrik Svensson, Magda N. Bictash

    The central role of the resident innate immune cells of the brain (microglia) in neurodegeneration has become clear over the past few years largely through genome-wide association studies (GWAS), and has rapidly become an active area of research. However, a mechanistic understanding (gene to function) has lagged behind. That is now beginning to change, as exemplified by a number of recent exciting and important reports that provide insight into the function of two key gene products – TREM2 (Triggering Receptor Expressed On Myeloid Cells 2) and PLCγ2 (Phospholipase C gamma2) – in microglia, and their role in neurodegenerative disorders. In this review we explore and discuss these recent advances and the opportunities that they may provide for the development of new therapies.